文献速递免疫规划传染病防控与疫情报告

比利时PCV13时代儿童肺炎球菌疫苗失败与突破性感染基线研究

Pneumococcal vaccines: A dose of change. Vaccine failures and breakthrough infections in Belgian children during the PCV13 era (2019-2024).
PubMed 文献 · Vaccine · 2025-12-05

该研究回顾性分析2019–2024年比利时≤5岁儿童侵袭性肺炎球菌病监测数据,在543例已知接种状态病例中识别26例疫苗失败(5.8%)和37例突破性感染(8.2%)。疫苗失败以19A、3、14血清型为主,与较大年龄和侵袭性肺炎相关;突破性感染以19A为主,多见于年幼儿童,为PCV20引入提供基线参考。

要点

  • PCV13时代比利时≤5岁儿童疫苗失败率5.8%,突破性感染率8.2%。
  • 疫苗失败主要血清型为19A(61.5%)、3(26.9%)、14(11.5%)。
  • 疫苗失败与较大年龄(OR 1.49)和侵袭性肺炎(OR 3.89)相关。

核心结论

  • 本研究提供了比利时PCV13时代儿童肺炎球菌疫苗失败的首个国家基线,可作为评估PCV20引入的参照点。

研究设计与样本

  • 回顾性队列研究,纳入2019–2024年比利时≤5岁侵袭性肺炎球菌病(IPD)儿童,数据来自国家侵袭性肺炎球菌参考中心监测和PediSurv网络。

主要发现

  • 543例已知接种状态的儿童IPD病例中,451例(83%)至少接种过一剂肺炎球菌结合疫苗。
  • 共识别26例疫苗失败(5.8%)和37例突破性感染(8.2%)。
  • 疫苗失败由血清型19A(61.5%)、3(26.9%)、14(11.5%)引起,与较大年龄(OR: 1.49; 95% CI: 1.18-1.89)和侵袭性肺炎(OR: 3.89; 95% CI: 1.66-9.12)相关。
  • 突破性感染涉及血清型19A(70.3%)、3(13.5%)、14(13.5%)、19F(2.7%),更常见于年幼儿童(OR: 0.61; 95% CI: 0.42-0.87)。
  • PCV10与PCV13突破性感染比例的差异主要由PCV13独有血清型驱动,调整后无显著差异。

临床怎么用

  • 监测儿童IPD时需关注疫苗失败和突破性感染,尤其19A、3、14血清型。
  • 对较大年龄儿童发生侵袭性肺炎应警惕疫苗失败可能。
  • PCV20引入后需持续监测以评估真实世界影响并指导免疫策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since 2019, PCV13 has replaced PCV10 in Belgium's childhood vaccination program, reducing IPD cases caused by PCV13 serotypes, mainly 19A, but accompanied by serotype replacement. This changing epidemiology prompted consideration of the higher-valent PCV20 vaccine. Despite broader serotype coverage, clinical effectiveness against certain serotypes remains uncertain, raising concerns about vaccine failures. To date, vaccine failures and breakthrough infections have not been systematically studied in Belgium. This study aims to establish a baseline by characterizing vaccine failures and breakthrough infections in children 0-5 years old during the recent PCV13 era, providing a reference point ahead of PCV20 introduction. METHODS: We conducted a retrospective cohort study including children ≤5 years diagnosed with IPD in Belgium from 2019 to 2024, using surveillance data from the National Reference Centre for invasive pneumococci and the PediSurv network. Vaccine failures and breakthrough infections were identified and characterized by serotype and clinical characteristics. RESULTS: Of 543 pediatric IPD cases with known vaccination status, 451 (83 %) had received at least one dose of pneumococcal conjugate vaccine. Among these, we identified 26 vaccine failures (5.8 %) and 37 breakthrough infections (8.2 %). Differences in breakthrough proportions between PCV10 and PCV13 were primarily driven by PCV13-exclusive serotypes, after adjustment no significant differences remained. Vaccine failures were caused by serotypes 19A (61.5 %), 3 (26.9 %), and 14 (11.5 %), and were associated with older age (OR: 1.49; 95 % CI: 1.18-1.89) and invasive pneumonia (OR: 3.89; 95 % CI: 1.66-9.12). Breakthrough infections involved serotypes 19A (70.3 %), 3 (13.5 %), 14 (13.5 %), and 19F (2.7 %) and occurred more often in younger children (OR: 0.61; 95 % CI: 0.42-0.87). CONCLUSION: These findings provide the first national baseline of vaccine failures, offering a reference point for evaluating PCV20 introduction. Continued monitoring will be essential to assess the real-world impact of higher-valent pneumococcal vaccines and to guide evidence-based vaccination policy.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dambre C, Cornelissen L, Cuypers L, et al. Pneumococcal vaccines: A dose of change. Vaccine failures and breakthrough infections in Belgian children during the PCV13 era (2019-2024). Vaccine. 2025. PMID: 41351928. doi:10.1016/j.vaccine.2025.128065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。